In order to ensure the highest quality of our services, we use small files called cookies. When using our website, the cookie files are downloaded onto your device. You can change the settings of your browser at any time. In addition, your use of our website is tantamount to your consent to the processing of your personal data provided by electronic means.

Chief Pharmaceutical Inspectorate

Counteracting corruption

The Chief Pharmaceutical Inspectorate has implemented numerous anti-corruption mechanisms. You can find detailed information on the key mechanisms on this website.


The Chief Pharmaceutical Inspectorate has established what areas and what positions can be exposed to corruption and, subsequently, has implemented anti-corruption procedures to reduce the related risk.


The area of the operations of the Chief Pharmaceutical Inspector that is potentially exposed to the corruption risk to the largest extent is contacts with external clients in relation to inspections of wholesale trade and manufacture of medicinal products.


The most important anti-corruption mechanisms include:

  1. The Anti-corruption Policy of the Chief Pharmaceutical Inspectorate – an internal procedure based on the obligation to maintain the internal system of alerts and responses to irregularities, observing irregularities that could potentially constitute a threat, monitoring the corruption risks in the internal control system, as well as monitoring positions at risk of corruption events and internal documents in terms of improving the system for eliminating corruption risks.
  2. Determining corruption risks and positions at risk of corruption. The area of operations that is potentially exposed to the risk of corruption to the largest extent is contacts with external clients.
  3. Procedures setting out the conduct in contacts with external clients.
  4. Mechanism of reporting irregularities and corruption risks for employees, guaranteeing the anonymous path of reporting.
  5. Mechanism preventing the conflict of interest in positions responsible for performing pharmaceutical supervision tasks, such as determining the rules of extra employment/paid activities.
  6. Gift policy prohibiting acceptance of any gifts.
  7. Anti-corruption education and building anti-corruption culture – the Chief Pharmaceutical Inspectorate conducts training as part of onboarding, preparatory service, and cyclic training courses. The Chief Pharmaceutical Inspector has appointed the Anti-corruption Action Coordinator and the Ethics Advisor.

Anti-corruption actions addressed to the Inspectorate employees:

  • Onboarding

Onboarding involves induction of a new Inspectorate employee by introducing them to the workplace and rules that apply there. Onboarding is based on the range of internal training courses conducted by internal instructors (Inspectorate employees). The training covers aspects relating to the legislation on civil service ethics as well as corruption and anti-corruption solutions applicable in the Inspectorate. The training is conducted by the Anti-corruption Action Coordinator.

  • Preparatory service

Employees who are starting to work as civil servants must undertake preparatory service. It is aimed at preparing them for the proper performance of duties. As part of a preparatory service in the Inspectorate, it is mandatory to complete an e-learning course within ethics and counteracting corruption. The training covers aspects relating to the legislation on civil service ethics as well as corruption and anti-corruption solutions applicable in the Inspectorate.

  • Anti-corruption Action Coordinator
  • Ethics Advisor

In the Chief Pharmaceutical Inspectorate, an Ethics Advisor has been appointed. Their tasks include:

  • advising and informing employees with regard to proper conduct and ethical aspects;
  • conducting notification and educational activities related to ethical issues and combating corruption;
  • supporting, assessing, and initiating actions to counteract and prevent coorruption in the office.
  • Obligation to submit property statements.
  • Obligation to submit conflict of interest statements.

Pursuant to Article 114a of the Pharmaceutical Law Act, the Chief Pharmaceutical Inspector, the deputy Chief Pharmaceutical Inspector, a voivodeship pharmaceutical inspector, a deputy voivodeship pharmaceutical inspector, pharmaceutical inspectors, GMP inspectors of the Chief Pharmaceutical Inspectorate, wholesale inspectors of the Chief Pharmaceutical Inspectorate, as well as persons in the Chief Pharmaceutical Inspectorate who perform activities related to the supervision of medicinal products, active substances, or excipients must submit conflict of interest statements.

  • Gift Policy

The Inspectorate has implemented a Gift Policy. In accordance with this policy, the employees must comply with the general prohibition against accepting any gifts, regardless of their value.

  • Code of Conduct in Corruption Situations

The Inspectorate has implemented a Code of Conduct in Corruption Situations. Its goal is to ensure fast and effective reaction to corruption events or suspected corruption events.


Reporting corruption
Each case of corruption can be reported to:

  • the police;
  • prosecutor’s office;
  • Central Anti-Corruption Bureau.

Remember that you can also report corruption to:

  • the Chief Pharmaceutical Inspector;
  • the Minister of Health.

 

{"register":{"columns":[]}}